CoChat
Sign Up
Cited by 48

The DOI matches its Crossref record.

Japanese cedar and cypress pollinosis updated: New allergens, cross-reactivity, and treatment

Osada, Toshihiro, Okano, Mitsuhiro·2021·Allergology International
DOI 10.1016/j.alit.2021.04.002
Open this paper in CoChat — free account

Abstract

Pollen from many tree species in the Cupressaceae family is a well-known cause of seasonal allergic diseases worldwide. Japanese cedar pollinosis and Japanese cypress pollinosis, which are caused by pollen from Japanese cedar (Cryptomeria japonica) and Japanese cypress (Chamaecyparis obtusa), respectively, are the most prevalent seasonal allergic diseases in Japan. Recently, the novel major Japanese cypress allergen Cha o 3 and the homologous Japanese cedar allergen Cry j cellulase were identified, and it was shown, for the first time, that cellulase in plants is allergenic. Although the allergenic components of pollen from both species exhibit high amino acid sequence identity, their pollinosis responded differently to allergen-specific immunotherapy (ASIT) using a standardized extract of Japanese cedar pollen. Pharmacotherapy and ASIT for Japanese cedar and cypress pollinosis have advanced considerably in recent years. In particular, Japanese cedar ASIT has entered a new phase, primarily in response to the generation of updated efficacy data and the development of new formulations. In this review, we focus on both Japanese cypress and cedar pollinosis, and discuss the latest findings, newly identified causative allergens, and new treatments. To manage pollinosis symptoms during spring effectively, ASIT for both Japanese cedar and Japanese cypress pollen is considered necessary.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.alit.2021.04.002

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 103

  1. Mao, 2012, Distribution of living Cupressaceae reflects the breakup of Pangea, Proc Natl Acad Sci U S A, 109, 7793, 10.1073/pnas.1114319109 · DOI
  2. Charpin, 2019, Cypress pollinosis: from tree to clinic, Clin Rev Allergy Immunol, 56, 174, 10.1007/s12016-017-8602-y · DOI · Paper page
  3. Honda, 2013, The relationship between pollen count levels and prevalence of Japanese cedar pollinosis in Northeast Japan, Allergol Int, 62, 375, 10.2332/allergolint.12-OA-0526 · DOI
  4. Kishikawa, 2016, Longitudinal investigation on allergenic conifer pollen in Japan for successful prevention and treatment against Japanese cedar pollinosis, Expert Opin Environ Biol, 5, 10.4172/2325-9655.1000132 · DOI
  5. Watanabe, 2020, [Comparison of the atmospheric dispersion of Japanese cypress and Japanese cedar pollen], Nippon Jibi Inkoka Gakkai Kaiho, 123, 139, 10.3950/jibiinkoka.123.139 · DOI
  6. Kishikawa, 2017, [Longitudinal monitoring of tree airborne pollen in Japan], [Jpn J Allergol], 66, 97
  7. Shah, 2020, Association between Japanese cedar and cypress pollen counts and climate factors over a 10-year period in Tsu city, Japan, Aerobiologia, 36, 291, 10.1007/s10453-020-09632-0 · DOI
  8. Hansen, 2006, Global temperature change, Proc Natl Acad Sci U S A, 103, 14288, 10.1073/pnas.0606291103 · DOI · Paper page
  9. Yamada, 2014, Present state of Japanese cedar pollinosis: the national affliction, J Allergy Clin Immunol, 133, 632, 10.1016/j.jaci.2013.11.002 · DOI
  10. Okano, 2012, Characterization of Japanese cypress pollinosis and the effects of early interventional treatment for cypress pollinosis, Clin Exp Allergy Rev, 12, 1, 10.1111/j.1472-9733.2011.01156.x · DOI
  11. Kawashima, 2016, [Efficacy of the cedar antigen-specific subcutaneous immunotherapy for Japanese cedar/cypress pollinosis], [Jpn J Rhinology], 55, 159, 10.7248/jjrhi.55.159 · DOI
  12. Suh, 2019, Number of seasonal exposures to Japanese cedar pollen increases the risk of sensitization: observational study in Korean adults, Sci Rep, 9, 10496, 10.1038/s41598-019-47124-5 · DOI
  13. Matsubara, 2020, [Epidemiological survey of allergic rhinitis in Japan 2019], [J Otolaryngol Jpn], 123, 485
  14. Urashima, 2018, Japanese cedar pollinosis in Tokyo residents born after massive national afforestation policy, Allergy, 73, 2395, 10.1111/all.13575 · DOI
  15. Yamamoto-Hanada, 2020, IgE responses to multiple allergen components among school-aged children in a general population birth cohort in Tokyo, World Allergy Organ J, 13, 100105, 10.1016/j.waojou.2020.100105 · DOI
  16. Okuda, 2003, Epidemiology of Japanese cedar pollinosis throughout Japan, Ann Allergy Asthma Immunol, 91, 288, 10.1016/S1081-1206(10)63532-6 · DOI
  17. Baba, 2008, [Epidemiology of nasal allergy through Japan in 2008], [Progress Med], 28, 2001
  18. Agea, 2002, The biology of cypress allergy, Allergy, 57, 959, 10.1034/j.1398-9995.2002.23832_4.x · DOI
  19. Itoh, 2020, [Changes in the level of dispersion and the degree of antigen sensitization of Japanese cedar and cypress pollen in allergic rhinitis patients in Hiroshima Prefecture], [Pract Otol Kyoto], 113, 481, 10.5631/jibirin.113.481 · DOI
  20. Ogihara, 2011, Increased throat symptoms in Japanese cypress pollinosis, J Otolaryngol Jpn, 114, 78
  21. Yasueda, 1983, Isolation and partial characterization of the major allergen from Japanese cedar (Cryptomeria japonica) pollen, J Allergy Clin Immunol, 71, 77, 10.1016/0091-6749(83)90550-X · DOI
  22. Sone, 1994, Cloning and sequencing of cDNA coding for Cry j I, a major allergen of Japanese cedar pollen, Biochem Biophys Res Commun, 199, 619, 10.1006/bbrc.1994.1273 · DOI
  23. Taniguchi, 1995, Cry j I, a major allergen of Japanese cedar pollen, has pectate lyase enzyme activity, Allergy, 50, 90, 10.1111/j.1398-9995.1995.tb02489.x · DOI
  24. Maeda, 2005, Glycoform analysis of Japanese cedar pollen allergen, Cry j 1, Biosci Biotechnol Biochem, 69, 1700, 10.1271/bbb.69.1700 · DOI
  25. Miki-Hirosige, 1994, Immunocytochemical localization of the allergenic proteins in the pollen of Cryptomeria japonica, Sex Plant Reprod, 7, 95, 10.1007/BF00230577 · DOI
  26. Yasueda, 2000, [Japanese ceder pollinosis and conifer pollen allergens], [Jpn J Palynol], 46, 29
  27. Hirahara, 2001, Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens, J Allergy Clin Immunol, 108, 94, 10.1067/mai.2001.115481 · DOI
  28. Osada, 2018, Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica (Japanese cedar) pollen: limitation of the present Japanese cedar-specific ASIT, Allergol Int, 67, 467, 10.1016/j.alit.2018.02.004 · DOI
  29. Sakaguchi, 1990, Identification of the second major allergen of Japanese cedar pollen, Allergy, 45, 309, 10.1111/j.1398-9995.1990.tb00501.x · DOI
  30. Pichler, 2015, Pectate lyase pollen allergens: sensitization profiles and cross-reactivity pattern, PLoS One, 10, e0120038, 10.1371/journal.pone.0120038 · DOI
  31. Sakaguchi, 1997, Epitope specificity of IgE antibodies to a major allergen (Cry j 1) of Japanese cedar pollen in sera of humans and monkeys with pollinosis, Immunology, 91, 161, 10.1046/j.1365-2567.1997.00255.x · DOI
  32. Takagi, 2005, Determination of human linear IgE epitopes of Japanese cedar allergen Cry j 1, Biol Pharm Bull, 28, 1496, 10.1248/bpb.28.1496 · DOI
  33. Suzuki, 1996, Purification, characterization and molecular cloning of Cha o 1, a major allergen of Chamaecyparis obtusa (Japanese cypress) pollen, Mol Immunol, 33, 451, 10.1016/0161-5890(95)00147-6 · DOI
  34. Kimura, 2008, Glycoform analysis of Japanese cypress pollen allergen, Cha o 1: a comparison of the glycoforms of cedar and cypress pollen allergens, Biosci Biotechnol Biochem, 72, 485, 10.1271/bbb.70572 · DOI
  35. Midoro-Horiuti, 1999, Molecular cloning of the mountain cedar (Juniperus ashei) pollen major allergen, Jun a 1, J Allergy Clin Immunol, 104, 613, 10.1016/S0091-6749(99)70332-5 · DOI
  36. Sone, 2005, Identification of human T cell epitopes in Japanese cypress pollen allergen, Cha o 1, elucidates the intrinsic mechanism of cross-allergenicity between Cha o 1 and Cry j 1, the major allergen of Japanese cedar pollen, at the T cell level, Clin Exp Allergy, 35, 664, 10.1111/j.1365-2222.2005.02221.x · DOI
  37. Ito, 1996, Analysis of the allergenic components of Hinoki cypress (Chamaecyparis obtusa) pollen by immunoblotting with the sera from patients with Japanese cedar pollinosis, Allergol Int, 45, 181, 10.2332/allergolint.45.181 · DOI
  38. Midoro-Horiuti, 2006, Structural basis for epitope sharing between group 1 allergens of cedar pollen, Mol Immunol, 43, 509, 10.1016/j.molimm.2005.05.006 · DOI
  39. Komiyama, 1994, cDNA cloning and expression of Cry j II the second major allergen of Japanese cedar pollen, Biochem Biophys Res Commun, 201, 1021, 10.1006/bbrc.1994.1804 · DOI
  40. Ohtsuki, 1995, Cry j 2, a major allergen of Japanese cedar pollen, shows polymethylgalacturonase activity, Allergy, 50, 483, 10.1111/j.1398-9995.1995.tb01183.x · DOI
  41. Nakamura, 2004, [Immunocytochemical localization of Cry j l and Cry j 2 the allergenic proteins of Japanese cedar pollen in the germinated pollen], [Jpn J Palynol], 50, 15
  42. Goto-Fukuda, 2007, [Investigation of the variation of Cry j 2 concentration in pollen among sugi (Cryptomeria japonica d. Don) trees using a newly established extraction method], [Jpn J Allergol], 56, 1262
  43. Tamura, 2003, Analysis of sequential immunoglobulin E-binding epitope of Japanese cedar pollen allergen (Cry j 2) in humans, monkeys and mice, Clin Exp Allergy, 33, 211, 10.1046/j.1365-2222.2003.01579.x · DOI
  44. Miyaji, 2013, Analysis of conformational and sequential IgE epitopes on the major allergen Cry j 2 of Japanese cedar (Cryptomeria japonica) pollen in humans by using monoclonal antibodies for Cry j 2, J Clin Immunol, 33, 977, 10.1007/s10875-013-9880-7 · DOI
  45. Mori, 1999, Purification, identification, and cDNA cloning of Cha o 2, the second major allergen of Japanese cypress pollen, Biochem Biophys Res Commun, 263, 166, 10.1006/bbrc.1999.1261 · DOI
  46. Yasueda, 2000, Identification and characterization of a group 2 conifer pollen allergen from Chamaecyparis obtusa, a homologue of Cry j 2 from Cryptomeria japonica, Clin Exp Allergy, 30, 546, 10.1046/j.1365-2222.2000.00747.x · DOI
  47. Sone, 2009, Recognition of T cell epitopes unique to Cha o 2, the major allergen in Japanese cypress pollen, in allergic patients cross-reactive to Japanese cedar and Japanese cypress pollen, Allergol Int, 58, 237, 10.2332/allergolint.08-OA-0027 · DOI
  48. Miyaji, 2016, Cross-reactivity between major IgE core epitopes on Cry j 2 allergen of Japanese cedar pollen and relevant sequences on Cha o 2 allergen of Japanese cypress pollen, Allergol Int, 65, 286, 10.1016/j.alit.2016.01.003 · DOI
  49. Futamura, 2002, Isolation and characterization of cDNAs that encode homologs of a pathogenesis-related protein allergen from Cryptomeria japonica, Biosci Biotechnol Biochem, 66, 2495, 10.1271/bbb.66.2495 · DOI
  50. Midoro-Horiuti, 2000, Variable expression of pathogenesis-related protein allergen in mountain cedar (Juniperus ashei) pollen, J Immunol, 164, 2188, 10.4049/jimmunol.164.4.2188 · DOI
  51. Fujimura, 2007, Isolation and characterization of native Cry j 3 from Japanese cedar (Cryptomeria japonica) pollen, Allergy, 62, 547, 10.1111/j.1398-9995.2007.01331.x · DOI
  52. Palacin, 2012, The involvement of thaumatin-like proteins in plant food cross-reactivity: a multicenter study using a specific protein microarray, PLoS One, 7, e44088, 10.1371/journal.pone.0044088 · DOI · Paper page
  53. Osada, 2016, Identification and gene cloning of a new major allergen Cha o 3 from Chamaecyparis obtusa (Japanese cypress) pollen, J Allergy Clin Immunol, 138, 911, 10.1016/j.jaci.2016.03.026 · DOI
  54. Osada, 2020, Identification of dominant T-cell epitopes in the major Japanese cypress pollen allergen Cha o 3, Allergol Int, 69, 141, 10.1016/j.alit.2019.07.008 · DOI
  55. Osada, 2017, Glycoform of a newly identified pollen allergen, Cha o 3, from Chamaecyparis obtusa (Japanese cypress, Hinoki), Carbohydr Res, 448, 18, 10.1016/j.carres.2017.05.005 · DOI
  56. Radauer, 2006, Pollen allergens are restricted to few protein families and show distinct patterns of species distribution, J Allergy Clin Immunol, 117, 141, 10.1016/j.jaci.2005.09.010 · DOI
  57. Yonekura, 2018, [A validation study of the improved product for measuring Japanese cypress pollen-specific IgE (thermo scientific(TM) ImmunoCAP(TM) ImmunoCAP Japanese cypress Pollen-specific IgE)], [Jpn J Allergol], 67, 67
  58. Di Felice, 1994, Allergens of Arizona cypress (Cupressus arizonica) pollen: characterization of the pollen extract and identification of the allergenic components, J Allergy Clin Immunol, 94, 547, 10.1016/0091-6749(94)90212-7 · DOI
  59. Shahali, 2010, IgE reactivity to common cypress (C. sempervirens) pollen extracts: evidence for novel allergens, World Allergy Organ J, 3, 229, 10.1097/WOX.0b013e3181eb3525 · DOI
  60. Fujimura, 2005, Molecular cloning of a class IV chitinase allergen from Japanese cedar (Cryptomeria japonica) pollen and competitive inhibition of its immunoglobulin E-binding capacity by latex C-serum, Clin Exp Allergy, 35, 234, 10.1111/j.1365-2222.2005.02167.x · DOI
  61. Kawamoto, 2002, Molecular cloning and characterization of a new Japanese cedar pollen allergen homologous to plant isoflavone reductase family, Clin Exp Allergy, 32, 1064, 10.1046/j.1365-2222.2002.01405.x · DOI
  62. Ibrahim, 2010, A new lipid transfer protein homolog identified as an IgE-binding antigen from Japanese cedar pollen, Biosci Biotechnol Biochem, 74, 504, 10.1271/bbb.90685 · DOI
  63. Ibrahim, 2010, Molecular cloning and immunochemical characterization of a new Japanese cedar pollen allergen homologous to plant subtilisin-like serine protease, World Allergy Organ J, 3, 262, 10.1097/WOX.0b013e318201d81d · DOI
  64. Ibrahim, 2010, Molecular cloning and immunochemical characterization of a novel major Japanese cedar pollen allergen belonging to the aspartic protease family, Int Arch Allergy Immunol, 152, 207, 10.1159/000283026 · DOI
  65. Takashima, 2019, Crystal structure and biochemical characterization of CJP38, a beta-1,3-glucanase and allergen of Cryptomeria japonica pollen, Mol Immunol, 116, 199, 10.1016/j.molimm.2019.10.016 · DOI
  66. Ehrenberg, 2020, Characterization of a 7 kDa pollen allergen belonging to the gibberellin-regulated protein family from three Cupressaceae species, Clin Exp Allergy, 50, 964, 10.1111/cea.13675 · DOI
  67. Inomata, 2020, Gibberellin-regulated protein allergy: clinical features and cross-reactivity, Allergol Int, 69, 11, 10.1016/j.alit.2019.10.007 · DOI · Paper page
  68. Sakashita, 2021, Comparison of sensitization and prevalence of Japanese cedar pollen and mite-induced perennial allergic rhinitis between 2006 and 2016 in hospital workers in Japan, Allergol Int, 70, 89, 10.1016/j.alit.2020.07.004 · DOI
  69. Okubo, 2020, Japanese guidelines for allergic rhinitis 2020, Allergol Int, 69, 331, 10.1016/j.alit.2020.04.001 · DOI
  70. Mizuguchi, 2020, Elucidation of inverse agonist activity of bilastine, Pharmaceutics, 12, 525, 10.3390/pharmaceutics12060525 · DOI
  71. Farre, 2014, Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers, Br J Clin Pharmacol, 78, 970, 10.1111/bcp.12421 · DOI
  72. Hashiguchi, 2017, Therapeutic effect of bilastine in Japanese cedar pollinosis using an artificial exposure chamber (Ohio Chamber), Allergol Int, 66, 123, 10.1016/j.alit.2016.06.009 · DOI
  73. Mizuguchi, 2012, Inverse agonistic activity of antihistamines and suppression of histamine H1 receptor gene expression, J Pharmacol Sci, 118, 117, 10.1254/jphs.11177SC · DOI
  74. Wu, 2004, Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 Receptor, Int Arch Allergy Immunol, 135, 313, 10.1159/000082325 · DOI
  75. Okubo, 2016, A Phase III clinical trial of desloratadine in Japanese subjects with seasonal allergic rhinitis-A randomized controlled trial-, J Clin Therap Med, 32, 863
  76. Okubo, 2019, Efficacy and safety of rupatadine in Japanese patients with seasonal allergic rhinitis: a double-blind, randomized, multicenter, placebo-controlled clinical trial, Allergol Int, 68, 207, 10.1016/j.alit.2018.08.011 · DOI
  77. Merlos, 1997, Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF), J Pharmacol Exp Ther, 280, 114, 10.1016/S0022-3565(24)36413-4 · DOI
  78. Vuurman, 2007, Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers, Hum Psychopharmacol, 22, 289, 10.1002/hup.856 · DOI
  79. Barbanoj, 2006, Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers, Hum Psychopharmacol, 21, 13, 10.1002/hup.741 · DOI
  80. Barbanoj, 2004, Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers, Neuropsychobiology, 50, 311, 10.1159/000080959 · DOI
  81. Okubo, 2018, Allergol Int, 67, 371, 10.1016/j.alit.2017.12.005 · DOI
  82. Mizuguchi, 2010, Preseasonal prophylactic treatment with antihistamines suppresses nasal symptoms and expression of histamine H(1) receptor mRNA in the nasal mucosa of patients with pollinosis, Methods Find Exp Clin Pharmacol, 32, 745, 10.1358/mf.2010.32.10.1533687 · DOI
  83. Yonekura, 2013, Randomized double-blind study of prophylactic treatment with an antihistamine for seasonal allergic rhinitis, Int Arch Allergy Immunol, 162, 71, 10.1159/000350926 · DOI · Paper page
  84. Higaki, 2012, Early interventional treatment with intranasal corticosteroids compared with postonset treatment in pollinosis, Ann Allergy Asthma Immunol, 109, 458, 10.1016/j.anai.2012.08.016 · DOI
  85. Makihara, 2012, Early interventional treatment with intranasal mometasone furoate in Japanese cedar/cypress pollinosis: a randomized placebo-controlled trial, Allergol Int, 61, 295, 10.2332/allergolint.11-OA-0382 · DOI
  86. Haruna, 2019, Determining an appropriate time to start prophylactic treatment with intranasal corticosteroids in Japanese cedar pollinosis, Med Sci (Basel), 7, 11
  87. Yonekura, 2009, Beneficial effects of leukotriene receptor antagonists in the prevention of cedar pollinosis in a community setting, J Investig Allergol Clin Immunol, 19, 195
  88. Sasaki, 2009, Cedar and cypress pollinosis and allergic rhinitis: quality of life effects of early intervention with leukotriene receptor antagonists, Int Arch Allergy Immunol, 149, 350, 10.1159/000205581 · DOI
  89. Okubo, 2020, Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study, J Allergy Clin Immunol Pract, 8, 3130, 10.1016/j.jaip.2020.04.068 · DOI
  90. Ogihara, 2010, [Quality of life in allergic rhinitis immunotherapy for Japanese cedar pollen], [Jpn J Rhinology], 49, 26, 10.7248/jjrhi.49.26 · DOI
  91. Okamoto, 2015, Efficacy and safety of sublingual immunotherapy for two seasons in patients with Japanese cedar pollinosis, Int Arch Allergy Immunol, 166, 177, 10.1159/000381059 · DOI
  92. Gotoh, 2019, Long-term efficacy and dose-finding trial of Japanese cedar pollen sublingual immunotherapy tablet, J Allergy Clin Immunol Pract, 7, 1287, 10.1016/j.jaip.2018.11.044 · DOI
  93. Yonekura, 2019, Treatment duration-dependent efficacy of Japanese cedar pollen sublingual immunotherapy: evaluation of a phase II/III trial over three pollen dispersal seasons, Allergol Int, 68, 494, 10.1016/j.alit.2019.05.002 · DOI
  94. Gotoh, 2020, Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet, Allergol Int, 69, 104, 10.1016/j.alit.2019.07.007 · DOI
  95. Yonekura, 2018, An analysis of factors related to the effect of sublingual immunotherapy on Japanese cedar pollen induced allergic rhinitis, Allergol Int, 67, 201, 10.1016/j.alit.2017.07.005 · DOI
  96. Nomura, 2021, Long-term treatment of Japanese cedar pollinosis with Japanese cedar pollen SLIT drops and persistence of treatment effect: a post-marketing clinical trial, Allergol Int, 70, 96, 10.1016/j.alit.2020.05.008 · DOI
  97. Kikuoka, 2020, Immunological effects of sublingual immunotherapy with Japanese cedar pollen extract in patients with combined Japanese cedar and Japanese cypress pollinosis, Clin Immunol, 210, 108310, 10.1016/j.clim.2019.108310 · DOI
  98. Yuta, 2007, [Efficacy of immunotherapy with Japanese cedar pollen extract for cypress pollinosis], [Jpn J Rhinology], 46, 109, 10.7248/jjrhi1982.46.2_109 · DOI
  99. Yuta, 2015, [Clinical efficacy for cypress pollinosis by sublingual immunotherapy for Japanese cedar pollen], [Jpn J Rhinology], 54, 503, 10.7248/jjrhi.54.503 · DOI
  100. Yuta, 2017, [Clinical efficacy of sublingual immunotherapy with Japanese cedar pollen during the cypress pollen season], [J Otolaryngol Jpn], 120, 833
  101. Okano, 2011, Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis, J Allergy Clin Immunol, 127, 277, 10.1016/j.jaci.2010.09.029 · DOI
  102. Ito, 1995, Specific IgE to Japanese cypress (Chamaecyparis obtusa) in patients with nasal allergy, Ann Allergy Asthma Immunol, 74, 299
  103. Hyo, 2018, Effectiveness of immunotherapy for cedar and cypress pollinosis, Pract Otol Kyoto, 111, 227, 10.5631/jibirin.111.227 · DOI

Cited by

Sorted by citations

Metadata

Authors
Osada, T., & Okano, M.
ORCID
Osada, Toshihiro
Venue
Allergology International
Publisher
Elsevier BV
Published
2021-07
Volume
70
Issue
3
Pages
281-290
ISSN
1323-8930
DOI
10.1016/j.alit.2021.04.002
Cited by
48
References
0
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review